Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT

Jakob R Passweg; Helen Baldomero; Fabio Ciceri; Rafael de la Cámara; Bertram Glass; Raffaella Greco; Mette D Hazenberg; Krzysztof Kalwak; Donal P McLornan; Bénédicte Neven; Zinaida Perić; Antonio M Risitano; Annalisa Ruggeri; John A Snowden; Anna Sureda

doi:10.1038/s41409-024-02248-9

Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT

Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02248-9. Online ahead of print.

Authors

Affiliations

¹ EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland.
² EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland. helen.baldomero@usb.ch.
³ Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
⁴ Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain.
⁵ Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
⁶ Department of Hematology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.
⁷ Clinical Department of Pediatric BMT, Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.
⁸ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
⁹ Pediatric immune-hematology unit, Necker Children Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
¹⁰ School of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia.
¹¹ Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale "San Giuseppe Moscati" (A.O.R.N. Giuseppe Moscati), Avellino, Italy.
¹² Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
¹³ Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

PMID: 38438647
DOI: 10.1038/s41409-024-02248-9

Abstract

In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (-4.0%) and autologous HCT (-1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26.2%) and non-malignant disorders (2572; 14.4%). Main indications for autologous HCT were lymphomas (7897; 32.9%), PCD (13,694; 57.1%) and solid tumors (1593; 6.6%). In allogeneic HCT, use of sibling donors decreased by -7.7%, haploidentical donors by -6.3% and unrelated donors by -0.9%. Overall cord blood HCT decreased by -16.0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down.